Literature DB >> 6977578

Characterization of two subsets of human T gamma cells.

R J van de Griend, I ten Berge, H J Tanke, D Roos, P T Schellekens, C J Melief, W P Zeijlemaker, A Astaldi.   

Abstract

Normal human E rosette-forming, Fc-IgG receptor-bearing cells (so-called T gamma cells) were separated into two functionally different subpopulations. Both subpopulations bind the monoclonal antibody OKM1 (directed against an antigen present also on monocytes and granulocytes). The first subpopulation accounts for about 70% of the total T gamma cell population, does not bind OKT3 (a monoclonal antibody directed against an antigen present on most T lymphocytes), and displays strong killer (K) cell and natural killer (NK) cell activity. The second subpopulation accounts for about 30% of the total T gamma population, binds both OKT3 and OKM1 (confirmed with a double-labeling assay), and displays low K and NK cell activity. Each subset contained less than 10% null cells. Comparison of T gamma cell populations obtained by adherence to a monolayer of IgG-coated human erythrocytes or by rosette formation with these cells revealed that pure T gamma cells with normal killer cell and natural killer cell activity were best obtained with the monolayer technique. Comparison of the enzymic and functional profile of T gamma cells, monocytes and granulocytes, as well as changes during culture of these cells in vitro, failed to indicate a relationship between T gamma cells and cells of the myelomonocytic lineage.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6977578

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin.

Authors:  K Sawada; S B Krantz; J S Kans; E N Dessypris; S Sawyer; A D Glick; C I Civin
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

2.  Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. II. Effector cells for the enhancing effect of acroscleroderma patients' sera.

Authors:  I J Polakowski; S Majewski; E Skopińska-Rózewska; M Zukowska; B Włodarska; S Jabłońska
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

3.  Natural killer (NK)-cell activity in sorted subsets of peripheral blood mononuclear cells from patients with severe combined immunodeficiency.

Authors:  R J ten Berge; P T Schellekens; A Budding-Koppenol; L J Dooren; J M Vossen
Journal:  J Clin Immunol       Date:  1987-05       Impact factor: 8.317

4.  Antibody-dependent cell-mediated cytotoxicity. Effectors, signals, and mechanisms.

Authors:  E W Fuson; R A Hubbard; D G Sugantharaj; R B Andrews; M R Beard; R L Whittaker
Journal:  Surv Immunol Res       Date:  1983

5.  Use of monoclonal antibodies as a diagnostic tool in human leukemia. I. Acute myeloid leukemia and acute phase of chronic myeloid leukemia.

Authors:  F Herrmann; B Komischke; E Odenwald; W D Ludwig
Journal:  Blut       Date:  1983-09

6.  Regulatory roles of T mu and T gamma cells in the collaborative cellular initiation of the extrinsic coagulation pathway by bacterial lipopolysaccharide.

Authors:  G A Levy; B S Schwartz; L K Curtiss; T S Edgington
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

7.  Recruitment of OKM1 staining lymphocytes with selective binding to K-562 tumour targets by interferon.

Authors:  R A Salata; B Z Schacter; J J Ellner
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

Review 8.  The human C3b receptor.

Authors:  D T Fearon
Journal:  Springer Semin Immunopathol       Date:  1983

9.  T gamma lymphocytosis is clinically non-progressive but immunologically heterogeneous.

Authors:  F Miedema; F G Terpstra; J W Smit; J P van der Veen; C J Melief
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

10.  Isolation and partial characterization of a novel subset of human T lymphocytes defined by monoclonal antibodies.

Authors:  R J Van de Griend; H G De Bruin; H C Rümke; R Van Doorn; D Roos; A Astaldi
Journal:  Immunology       Date:  1982-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.